Gemcitabine Revolutionizes Breast Cancer Treatment

Gemcitabine Revolutionizes Breast Cancer Treatment

Triple Negative Breast Cancer (TNBC) remains one of the most aggressive and challenging subtypes of breast cancer to treat, primarily due to its lack of targeted therapy options. However, a recent study conducted by a team of researchers led by Imene Tabet and Charles Theillet at the Institut de Recherche en Cancérologie de Montpellier, Montpellier University, has shed new light on a potential breakthrough in the treatment of TNBC, particularly in cases where the tumor exhibits BRCA1 deficiency.

BRCA1 and BRCA2 are well-known players in the homologous recombination (HR) DNA repair pathway. While their primary function is to repair DNA damage, they also play essential roles in protecting and repairing stalled DNA replication forks. Notably, BRCA1 deficiency is encountered in approximately 25% of TNBC cases. This deficiency has long been a subject of interest for researchers, as it presents a potential vulnerability that could be targeted for treatment.

In their study, Tabet and her team explored whether BRCA1-deficient TNBC cell models would exhibit increased sensitivity to replication poisons, specifically focusing on gemcitabine, a frequently used replication poison and a chain terminator. To do this, they compared the response of BRCA1-deficient TNBC cells with isogenic BRCA1-proficient cells when exposed to gemcitabine.

The results were striking. Gemcitabine treatment of BRCA1-deficient models led to a phenomenon known as replication catastrophe, resulting in massive cell death. This catastrophe was marked by a substantial accumulation of single-strand DNA (ssDNA) and DNA double-strand breaks (DSBs), along with an absence of the typical signals from the DNA repair proteins RPA and RAD51. These findings suggest that the replication forks in BRCA1-deficient cells were unable to cope with the stress imposed by gemcitabine, leading to extensive DNA damage and cell death.

The researchers also identified the underlying mechanisms responsible for the ssDNA accumulation in BRCA1-deficient cells. They found that uncontrolled resection of DNA by the MRE11 protein played a critical role, indicating that replication fork reversal was a significant response to replication poisoning. This process, essentially reversing the replication fork, exacerbates the accumulation of ssDNA, contributing to the observed replication catastrophe.

Furthermore, the study revealed that gemcitabine-treated BRCA1-deficient cells were not only prone to replication catastrophe but also to mitotic catastrophe. This caused the formation of micronuclei and mitotic bridges within the cells. Remarkably, these BrdU-positive micronuclei and DNA bridges activated the cGAS pathway, an innate immune response that detects DNA damage, leading to potential antitumor immune responses.

The implications of these findings are significant. Gemcitabine treatment, which is already in clinical use for various cancer types, may hold substantial promise for BRCA1-deficient TNBC patients. Not only does it induce cancer cell death through replication catastrophe, but it also triggers immune responses that could enhance the body's ability to combat the tumor. This suggests that gemcitabine treatment could be beneficial in two critical aspects: directly targeting and killing cancer cells while simultaneously stimulating the immune system to recognize and fight the tumor.

In conclusion, the research conducted by Imene Tabet and Charles Theillet's team presents a promising avenue for the treatment of BRCA1-deficient TNBC. This study not only highlights the vulnerabilities of BRCA1-deficient cells but also underscores the potential of gemcitabine as a valuable therapeutic option for this aggressive breast cancer subtype. While more research and clinical trials are needed to confirm these findings, the study opens up new possibilities for more effective and targeted treatments for TNBC patients, especially those with BRCA1 mutations.


Tabet, I., Orhan, E., Candiello, E., Fenou, L., Velazquez, C., Orsetti, B., Rodier, G., Jacot, W., Ribeyre, C., Sardet, C., & Theillet, C. (2023). Replication poison treated BRCA1-deficient breast cancers are prone to MRE11 over-resection resulting in single strand DNA accumulation and mitotic catastrophe. Cold Spring Harbor Laboratory.

Back to blog

Leave a comment

Best Sellers